|  |
| --- |
| **Lung transplant outcomes were not negatively affected by the COVID-19 pandemic in Western Australia** |
| Nicholas Peh1, Sharon Lawrence2, Michael Musk2, Melanie Lavender2, Meow Cheong Yaw2, Karim Slimani3, Agneta Geldenhuys3, Robert Larbalestier3, Jeremy Wrobel1,2 |
| *1 Department of Medicine, University of Notre Dame Australia, Perth, Australia*  *2 Advanced Lung Disease Unit, Fiona Stanley Hospital, Perth Australia*  *3 Cardiothoracic Surgery, Fiona Stanley Hospital, Perth, Australia* |
| **Introduction/Aim:**  Lung transplantation during the SARS-CoV-2 (COVID-19) pandemic may have inferior post-transplant outcomes due to increased risk of infection or challenges in health service delivery. We sought to determine if lung transplant recipients during the COVID-19 pandemic experienced worse short-term mortality and morbidity in comparison with a similar period immediately prior to the pandemic.  **Methods:**  We conducted a single centre retrospective cohort study. The COVID-19 pandemic period was defined as transplants undertaken in 2020 and 2021. The pre-pandemic period was defined as transplants undertaken in 2017 and 2018. The primary outcome was 30-day mortality. Secondary outcomes included 12-month mortality, major complication within 12 months (defined as non-elective surgery, ICU or HDU readmission during index admission, major cardiovascular event, tracheostomy, post-surgical ECMO, or renal replacement therapy), ICU length of stay and total hospital length of stay.  **Results:**  In total, 66 lung transplant recipients were assessed; 33 (50%) received lung transplantation in 2017 and 2018 prior to the COVID-19 pandemic and the remaining 33 transplant recipients underwent lung transplantation in 2020 and 2021 of the COVID-19 pandemic. 30-day survival in the pre-COVID-19 group and COVID-19 pandemic group were 93.9% and 97.0% respectively (p=ns). 12-month survival was 90.9% in both groups. Major complication within 12 months was 45.5% and 39.4% respectively (p=0.618). The mean ICU length of stay in days was 14.9 ± 21 in the pre-COVID-19 pandemic group and 12.8 ± 19.9 in the COVID-19 group (p=0.995). The mean hospital length of stay in days was 37.7 ± 32.1 in the pre-COVID-19 group and 37.4 ± 32.2 in the COVID-19 pandemic group (p=0.695).  **Conclusion:**  There were no significant differences in mortality or morbidity amongst lung transplant recipients during the COVID-19 pandemic compared with the pre-COVID-19 cohort in Western Australia.  **Grant Support:**  None.  **Key Words:** Lung transplantation, Mortality, COVID-19 |